Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 10, 2017

ThromboGenics begins patient enrolment for Phase II trial of THR-317 to treat diabetic macular edema

Belgium-based biopharmaceutical company ThromboGenics has initiated patient enrolment for its Phase II clinical study of THR-317 to treat diabetic macular edema (DME).

Belgium-based biopharmaceutical company ThromboGenics has initiated patient enrolment for its Phase II clinical study of THR-317 to treat diabetic macular edema (DME).

THR-317 (anti-PIGF) has been developed as a recombinant human monoclonal antibody, which targets the receptor-binding site of human placental growth factor (PlGF).

Its mechanism of action involves the reduction of blood vessel leakage, which prevents inflammation in early stage, non-proliferative diabetic retinopathy.

The Phase II study will be conducted as a singlemasked, multicentre exploratory study to test the safety and efficacy of two doses of THR-317 through intravitreal injections to treat DME.

It will also assess the ability of THR-317 to improve best corrected visual acuity (BCVA), as well as minimise central retinal thickness caused by DME.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The trial is expected to enrol 50 patients and will release its result in the first quarter of 2018.

"We believe that our anti-PlGF antibody THR-317 holds the potential to differentiate and improve current standard of care for this important sight-threatening disease."

ThromboGenics CEO Dr Patrik De Haes said: “Knowing that 35% of all diabetes patients will in their lives develop some form of diabetic retinopathy (DR), there is a clear unmet medical need and an increasing demand for improved or add-on treatment options.

“We believe that our anti-PlGF antibody THR-317 holds the potential to differentiate and improve current standard of care for this important sight-threatening disease.”

Subject to the result of the currently held clinical trial, the company will further explore THR-317 functionality in addressing other DR indications.

The recently held preclinical trial has established benefits of THR-317 in treating DR.


Image: Eye blood vessels surrounded by hard exudates in a DME patient. Photo: courtesy of National Eye Institute, National Institutes of Health.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU